Kyoto, Japan
Kyoto, Japan

Kyoto University , or Kyodai is a national university located in Kyoto, Japan. It is the second oldest Japanese university, one of the highest ranked universities in Asia and one of Japan's National Seven Universities. One of Asia’s leading research-oriented institutions, Kyoto University is famed for producing world-class researchers, including ten Nobel Prize laureates, two Fields medalists and one Gauss Prize. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Kyoto University | Date: 2017-05-17

The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject.


A novel genetic factor for rheumatoid arthritis is searched for and used as a diagnostic marker. A method of testing for rheumatoid arthritis, comprising detecting an autoantibody to myelin basic protein in a biological sample from a subject. A test kit for rheumatoid arthritis, comprising myelin basic protein. A diagnostic marker for rheumatoid arthritis, comprising an antibody to myelin basic protein. A method of judging the risk to develop rheumatoid arthritis, comprising identifying the single nucleotide polymorphism of a nucleotide present in the myelin basic protein gene of a subject or identifying the single nucleotide polymorphism of a nucleotide that is in linkage disequilibrium with the first mentioned nucleotide. A kit for judging the risk to develop rheumatoid arthritis, comprising nucleic acid probes and/or nucleic acid primers capable of detecting the single nucleotide polymorphism of a nucleotide present in the myelin basic protein gene of a subject or the single nucleotide polymorphism of a nucleotide that is in linkage disequilibrium with the first mentioned nucleotide. A method of screening for a substance effective as a prophylactic and/or therapeutic for rheumatoid arthritis, comprising adding a test substance to a myelin basic protein gene-expressing cell and then determining the expression level of the myelin basic protein gene or the gene product thereof.


An object of the present invention is to provide a technology of dispersing cellulose readily in a hydrophobic substance such as a resin by treating cellulose being a hydrophilic substance in a system that contains water as a main medium with a polymer dispersant, which has been developed for dispersing a fine and hydrophobic substance such as a pigment, in a simple and efficient manner without conducting surface modification of nanocellulose or other treatments. The object is solved by a process for producing a readily dispersible cellulose composition, the process including dissolving a polymer dispersant having a block copolymer structure having a resin-affinitive segment A and a cellulose-adsorptive segment B in a hydrophilic organic solvent solution, adding a surface active agent to the resultant solution, thereafter adding water to the resultant mixture to prepare an aqueous dispersion treatment agent containing the polymer dispersant, and adding the obtained aqueous dispersion treatment agent to cellulose in a water-containing state or in a dry state, thereby obtaining a readily dispersible cellulose composition. The object is also solved by a process for producing an aqueous dispersion treatment agent for use in the process for producing a readily dispersible cellulose composition, the readily dispersible cellulose composition, and a cellulose-dispersed resin composition using the readily dispersible cellulose composition.


Patent
Sumitomo Heavy Industries and Kyoto University | Date: 2017-03-01

Provided is a neutron capture therapy system which can improve a therapeutic efficacy. A neutron capture therapy system (1) in which a patient (S) is irradiated with a neutron beam (N) includes an irradiation chamber (3) which is surrounded by a shielding wall (W) blocking the neutron beam (N) from being radiated from the inside to the outside of the chamber and in which the patient (S) is arranged inside the chamber and is irradiated with the neutron beam (N), a neutron beam irradiation unit (8) that irradiates the inside of the irradiation chamber (3) with the neutron beam (N), a shielding door (D1) that closes a gate (3b) provided in the shielding wall (W), a medicine supply pump (17) that supplies a medicine to the patient (S), and a medicine supply tube (18) through which the medicine is introduced from the medicine supply pump (17) to the patient (S) arranged inside the irradiation chamber (3). The medicine supply pump (17) has a control unit (17a) which controls a supply quantity of the medicine and is arranged outside the irradiation chamber (3).


The present invention provides a microfluidic device comprising at least one cell culture chamber, the or each chamber being connected to at least two openings, the device being configured to supply at least one physiologically active substance from at least one of the openings to the or each cell culture chamber in such a manner as to form a concentration gradient or concentration gradients in the or each chamber when cells and a hydrogel are introduced into the or each chamber to culture the cells in a 3D-gel medium.


Conventionally, it has been impossible to output an image that allows for an easy and accurate diagnosis as to whether or not a malignant tumor is present and that allows for correctly indicating a part with a high or low grade of malignancy in the tumor. With an image processing apparatus that includes: a receiving unit configured to receive diffusion weighted images; a parameter acquisition unit configured to acquire parameters of two or more types for each of one or more units of processing that constitute the diffusion weighted images, by using the diffusion weighted images; a diagnostic image composition unit configured to acquire, for each of the one or more units of processing, a score that corresponds to the parameters of two or more types, by using the parameters of two or more types, and to compose a diagnostic image that is an image having, for each of the one or more units of processing, a pixel value that corresponds to the acquired score that corresponds to the unit of processing; and an output unit configured to output the diagnostic image, it is possible to output an image that allows for an easy and accurate diagnosis as to whether or not a malignant tumor is present and that allows for correctly indicating a part with a high or low grade of malignancy in the tumor.


Patent
Kyoto University and ARKRAY Inc. | Date: 2017-01-04

Provided is a radioactive labeled compound that can detect a secondary mutation of an epidermal growth factor receptor and which is a compound represented by Formula (1) described below or a pharmaceutically acceptable salt thereof. In Formula (1), L_(1) is an alkanediyl group having 1 to 5 carbon atoms or an alkenediyl carbonyl group having 3 to 8 carbon atoms, R_(1) is a radioactive halogen atom, or 5- to 7-membered monocyclic nitrogen-containing heterocycloalkyl that may have one substituent, R_(2) is a 6- to 8-membered aryl group or nitrogen-containing heteroaryl group with one substituent, R_(1) or R_(2) contains a radioactive halogen atom or a radioactive carbon atom (^(11)C), and Y is -NH- or -O-.


Patent
Kyoto University | Date: 2017-09-20

The present invention provides a method for efficiently inducing CD8-positive T cells by adding vitamin C to the medium in the steps of induction of the CD8-positive T cells from pluripotent stem cells. The present invention also provides a method for efficiently inducing CD8-positive T cells by performing culture in a medium supplemented with an adrenocortical hormone agent in the step of induction of the CD8-positive T cells from CD4/CD8 double-positive T cells.


This invention provides a method for knock-in of a donor DNA into the genome of a cell, comprising introducing at least one artificial nuclease system capable of cleaving target sequence(s) of the cell genome, the donor DNA, and two single-stranded oligonucleotides (ssODNs) into the cell, the artificial nuclease system cleaving the target sequence(s) on the cell genome, the two ssODNs each complementary to one of the ends generated by the target sequence cleavage in the cell genome and to one of the introduction ends of the donor DNA, the donor DNA being knocked-in at the cleavage site via the two ssODNs.


Patent
Kyoto University | Date: 2017-09-20

An object of the present invention is to provide a method for screening for a prophylactic or therapeutic agent for tauopathy capable of blocking the propagation of tau-mediated neurodegeneration. A method for screening for a prophylactic or therapeutic agent for tauopathy, comprising the following steps (1) to (3):(1) contacting neurons having a mutant MAPT gene with a test substance;(2) measuring any one index selected from the group consisting of the following (a) to (e) in the neurons:(a) the amount of a tau oligomer in a culture supernatant,(b) the amount of an intracellular tau oligomer,(c) the frequency of depolarization,(d) an intracellular calcium ion concentration, and(e) the number of living cells; and(3) selecting the test substance as a prophylactic or therapeutic agent for tauopathy when the value of (a), (b), (c), or (d) measured in the step (2) after the contact with the test substance in the step (1) is lower than the value obtained without the contact with the test substance in the step (1), and/or when the value of (e) measured in the step (2) after the contact with the test substance in the step (1) is higher than the value obtained without the contact with the test substance in the step (1).

Loading Kyoto University collaborators
Loading Kyoto University collaborators